We use cookies to help improve your experience of our website. With your consent, statistical and analytical cookies may also be used on this website. If you agree to the use of these additional cookies, please mark your choice:

Accept Reject all
We use cookies to help improve your experience of our website. With your consent, statistical and analytical cookies may also be used on this website. If you agree to the use of these additional cookies, please mark your choice:
Back to testimonies

How the COVID Pandemic Has Revolutionized Genomics: Insights from Davide Cacchiarelli



In an exclusive interview with NewsMed, Davide Cacchiarelli, a prominent Molecular Biology and Genomics Professor at the University of Naples, discusses how the COVID-19 pandemic has played a pivotal role in highlighting the significance of genomic surveillance and advancing genomics research.

A Passion for Molecular Biology and Genomics

Davide Cacchiarelli introduces himself as a passionate Molecular Biology and Genomics Professor at the University of Naples. His fascination with genomics lies in its potential as an effective tool to enhance human health, unravel molecular intricacies within cells and nuclei, and offer profound insights into cellular and organismal functions.

The Power of a Multidisciplinary Approach

At the Telethon Institute of Genetics and Medicine (TIGEM), Davide Cacchiarelli and his team adopt a multidisciplinary approach combining cell biology, molecular biology, and genomics. This integrative approach has proven instrumental in addressing complex challenges, especially in the context of infectious diseases like COVID-19. By combining various omics data and patient outcomes, they gained deeper insights into COVID-19 behaviors within populations and clinical settings.

Focusing on Diverse Research Areas

At TIGEM, Davide Cacchiarelli's group explores a broad spectrum of research areas, ranging from fundamental microbiology to developmental biology. They leverage this knowledge to pioneer regenerative medicine and harness the power of genomics for medical purposes, ultimately impacting healthcare outcomes for patients in their region.

Unveiling New SARS-CoV-2 Sequencing Surveillance

The research carried out by Davide Cacchiarelli and his colleagues led to the publication of a significant paper titled "Improved SARS-CoV-2 sequencing surveillance allows the identification of new variants and signatures in infected patients." Their work focused on making COVID-19 genome sequencing cost-effective and efficient. By integrating genomic information with transcriptomic profiling of the patient airway epithelia, they tracked the virus's evolution and identified new viral variants more accurately.

Advantages of Identifying New Variants

Identifying and tracking new viral variants holds paramount importance for healthcare centers and patients alike. The ability to detect emerging variants promptly allows for better containment and management of pathogenic strains. Such vigilance plays a crucial role in safeguarding public health and preventing future pandemics.

MGI's Contribution to Genomics Research

Davide Cacchiarelli acknowledges MGI Tech's contributions to their research. MGI's cutting-edge genomics tools and technologies, including COVID and whole-genome sequencing solutions, played a crucial role in their study. MGI's commitment to providing customizable and efficient genomic solutions has been instrumental in advancing their research.

The Importance of Selecting the Right Sequencing Technology

Selecting the right sequencing technology is critical, particularly when identifying gene variants. Accuracy and reliability are of utmost importance to avoid errors and misinterpretation of data. MGI's technology, with its exceptionally low error rate in DNB sequencing, offers a robust solution for accurate genomic profiling.

Collaborations: Accelerating Research in Times of Crisis

Collaborations with diverse researchers have been instrumental in advancing their COVID-related research. By tapping into the expertise of virologists, MGI scientists, and genomic specialists, they could accelerate their efforts and achieve optimal results in a short timeframe. The pandemic highlighted the significance of collaborative efforts in tackling global health challenges effectively.

Gaining Insights for Future Preparedness

Understanding SARS-CoV-2 better through advanced genomics can be a game-changer in preparing for future pandemics. While the COVID-19 pandemic may not have immediately impacted healthcare, it has demonstrated the vital role of advanced genomics in tracking diseases and shaping government decisions. Today, laboratories worldwide have embraced genomic workflows, signifying a brighter future for global healthcare.

Omics for All: Genome Sequencing for Healthcare

The concept of "omics for all" emphasizes universal access to high-quality genomic profiling. However, Davide Cacchiarelli underscores the need for medical supervision, as genomic profiling is a medical procedure. The goal is to offer everyone access to this cutting-edge technology while ensuring proper medical oversight.

The Path Forward: Basic Research and Genomic Screening

As a visionary in the field of genomics, Davide Cacchiarelli plans to continue his basic research, focusing on pluripotent and stem cells for regenerative medicine. Moreover, the knowledge gained from COVID-19 sequencing will be applied to fast, cost-effective, and reliable genomic screening for hereditary cancers and other human disease-driving genes.

In conclusion, the COVID-19 pandemic has not only emphasized the importance of genomic surveillance but also spurred a revolution in genomics research and its applications in healthcare. Thanks to collaborative efforts and advanced technologies, we are better equipped to face future health challenges and pave the way for a healthier and more resilient global population.

About MGI

MGI Tech Co., Ltd. (MGI) is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine, and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users, and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit the MGI website or connect on TwitterLinkedIn, or YouTube.